Trial intelligence / Profile preview

Phase 3 study of zanubrutinib versus bendamustine + rituximab in previously untreated CLL/SLL

2017-001551-31Phase 3Unknown

Sponsor

BeiGene

Start

Sep 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1